Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India Jun 8, 2021
Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip May 17, 2021
Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19 May 3, 2021
Revive Therapeutics Announces Successful Research Results for OTF Psilocybin and Filing of U.S. Provisional Patent… Apr 22, 2021
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 Mar 24, 2021